Apogee Therapeutics released mid‑stage maintenance data showing its anti‑IL‑13 antibody zumilokibart maintained clinical benefit with less frequent dosing. In the Phase II maintenance readout, 75% of participants dosed once every three months and 85% dosed once every six months sustained EASI‑75 responses at one year, company statements and analyst notes said. The results produced an immediate positive market reaction and position Apogee as a potential competitor to existing biologics that require more frequent dosing. The company and external analysts caution that larger, confirmatory trials will be required to validate durability and safety before regulatory submissions.